导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.46% | 2082/4773 |
| 近一周 | -2.02% | 1085/5462 |
| 近一月 | -3.84% | 2008/5421 |
| 近一季 | -6.72% | 2178/5209 |
| 近半年 | -1.86% | 1710/4920 |
| 近一年 | 3.16% | 1981/4366 |
| 近两年 | 54.28% | 1360/2954 |
| 近三年 | 34.93% | 868/2253 |
| 成立以来 | 97.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.90% 2959/4961 |
13.77% 1945/5312 |
- - |
- - |
| 2025 | 22.54% 1961/4813 |
-0.49% 2274/3635 |
2.25% 1716/4076 |
19.61% 2124/4524 |
0.69% 1844/4813 |
| 2024 | 16.86% 751/3463 |
2.77% 707/2808 |
-1.24% 1001/3014 |
16.78% 1352/3129 |
-1.40% 1689/3463 |
| 2023 | -9.08% 1099/2656 |
4.10% 1051/2280 |
-4.77% 1283/2385 |
-2.56% 693/2515 |
-5.87% 1535/2655 |
| 2022 | -18.06% 656/2207 |
-14.49% 952/1919 |
7.96% 409/2016 |
-12.60% 741/2113 |
1.57% 1219/2208 |
| 2021 | 6.43% 514/1822 |
-2.48% 650/1255 |
9.35% 559/1330 |
-2.59% 584/1466 |
2.46% 588/1822 |
| 2020 | 46.80% 204/1250 |
-6.10% 457/1028 |
17.63% 367/1067 |
15.20% 231/1164 |
15.38% 212/1184 |
| 2019 | 39.29% 286/1092 |
26.60% 390/754 |
0.10% 200/804 |
1.69% 371/850 |
8.09% 355/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.33% 282/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 易方达MSCI中国A股ETF VS. 长安沪深300非周期A(740101) |